Morbidity and mortality during the first two years of life among uninfected children born to human immunodeficiency virus type 1-infected women: The women and infants transmission study

Pediatric Infectious Disease Journal

Volumn 24, Issue 1, 2005, Pages 46-56

  Paul, Mary E ^a,i   Chantry, Caroline J ^b   Read, Jennifer S ^c   Frederick, Margaret M ^d   Lu, Ming ^d   Pitt, Jane ^e   Turpin, Delmyra B ^f   Cooper, Ellen R ^g   Handelsman, Edward L ^h  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d Clinical Trials & Surveys Corp   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^h SUNY DOWNSTATE MEDICAL CENTER   (United States)

ⁱ TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Children; Human immunodeficiency virus infection; Human immunodeficiency virus uninfected; Morbidity

Indexed keywords

ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; BODY HEIGHT; CHILDHOOD MORTALITY; COMORBIDITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; WEIGHT GAIN; ADDICTION; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG COMBINATION; GROWTH; HOSPITALIZATION; INCIDENCE; MORBIDITY; MORTALITY; NEWBORN; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PREMATURITY; PRENATAL EXPOSURE; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CHILD, PRESCHOOL; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FEMALE; GROWTH; HIV INFECTIONS; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; MORBIDITY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; REVERSE TRANSCRIPTASE INHIBITORS; SUBSTANCE-RELATED DISORDERS;

EID: 13944253695     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000148879.83854.7e     Document Type: Article

References (51)

1. Lindegren ML, Byers RH Jr, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA. 1999;282:531-538.
2. CDC. U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR. 1995;44(RR-7):1-14.
3. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180.
4. CDC. Recommendations of the Public Health Service Task force on use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR. 1994;43(RR-11):1-21.
5. European Mode of Delivery Collaboration. Elective caesarean section versus vaginal delivery in preventing vertical HIV-1 transmission: a randomized clinical trial. Lancet. 1999;353:1035-1039.
6. International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med. 1999;340:977-987.
7. American College of Obstetricians and Gynecologists. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. In: American College of Obstetricians and Gynecologists Committee Opinion Number 234. Washington, DC: American College of Obstetricians and Gynecologists; 2000.
8. Read JS. Cesarean section delivery to prevent vertical transmission of human immunodeficiency virus type 1: associated risks and other considerations. Ann NY Acad Sci. 2000;918:115-121.
9. Public Health Service Task Force. Recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Available at: http://www.aidsinfo.nih.gov.
10. Dominguez KL, Lindegren ML, D'Almada PJ, et al. Increasing trend of cesarean deliveries in HIV-infected women in the United States from 1994 to 2000. J Acquir Immune Defic Syndr. 2003;33:232-238.
11. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.
12. Sheon AR, Fox HE, Rich KC, et al. Women and Infants Transmission Study (WITS) of maternal-infant HIV transmission: study, design, methods, and baseline data. J Womens Health. 1996;5:69-78.
13. McIntosh K, Pitt J, Brambilla D, et al. Blood culture in the first 6 months of life for the diagnosis of vertically transmitted human immunodeficiency virus infection. J Infect Dis. 1994;170:996-1000.
14. Diaz C, Hanson C, Cooper ER, et al. Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth: Women and Infant Transmission Study (WITS). J Acquir Immune Defic Syndr. 1998;18:221-228.
15. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR. 1994;43(RR-12):1-10.
16. Moye J Jr, Rich KC, Kalish LA, et al. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. J Pediatr. 1996;128:58-67.
17. World Health Organization. Measuring change in nutritional status: guidelines for assessing the nutritional impact of supplementary feeding programmes for vulnerable groups. Geneva, Switzerland: World Health Organization; 1983.
18. National Household Survey Capability Programme. How to weigh and measure children: assessing the nutritional status of young children in household surveys. New York, NY: United Nations Department of Technical Cooperation for Development and Statistical Office; 1986.
19. Hamil PV, Drizd TA, Johnson CZ, Reed RB, Roche AF, Moore WM. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr. 1979;32:607-629.
20. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002;109:45-60.
21. Dibley MJ, Staehling N, Nieburg P, Trowbridgee FL. Interpretation of Z-score anthropometric indicators derived from international growth reference. Am J Clin Nutr. 1987;46:749-762.
22. ANTHRO Software for Calculating Pediatric Anthropometry. version 1.01. Atlanta, GA: Centers for Disease Control and Prevention; 1990.
23. Calvelli T, Denny TN, Paxton H, Gelman R, Kagan J. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry. 1993; 14:702-715.
24. Paxton H, Kidd P, Landay A, et al. Results of the flow cytometry ACTG quality control program: analysis and findings. Clin Immunol Immunopathol. 1989;52:68-84.
25. Gelman R, Cheng SC, Kidd P, Waxdal M, Kagan J. Assessment of the effects of instrumentation, monoclonal antibody, and fluorochrome on flow cytometric immunophenotyping: a report based on two years of the NIAID DAIDS flow cytometry quality assessment program. Clin Immunol Immunopathol. 1993;66:150-162.
26. Rockcress BD. Hematology. In: Barone MA, ed. The Harriet Lane Handbook. St. Louis, MO: Mosby-Year Book, Inc.; 1996.
27. McCormick MC, Weinick RM, Elixhauser A, Stagnitti MN, Thompson J, Simpson L. Annual report on access to and utilization of health care for children and youth in the United States: 2000. Amb Pediatr. 2001;1:3-15.
28. Centers for Disease Control and prevention. CDC HIV/AIDS Surveillance Report 2002. Atlanta, GA: U.S. Department of Health and Human Services; 2002:14. Available at http://www.cdc.gov/hiv/stats/ hasrlink.htm.
29. Agostoni G, Zuccotti GV, Giovannini M, et al. Growth in the first two years of uninfected children born to HIV-1 seropositive mothers. Arch Dis Child. 1998;79:175-178.
30. McKinney RE, Robertson WR, Duke Pediatric AIDS Clinical Trials Unit. Effect of human immunodeficiency virus infection on the growth of young children. J Pediatr. 1993;123:579-582.
31. Dunn AM, Cervia J, Noel GJ, et al. Failure to thrive in the HIV-infected child. In: 11th International Conference of AIDS. Vancouver, Canada: Education International; 1996. (Abstract 1):319:2312.
32. Newell ML, Borja MC, Peckham C, European Collaborative Study. Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics. 2003;111:e52-e60.
33. Fox NL, Sexton M, Hebel JR. Prenatal exposure to tobacco, I: effects on physical growth at age three. Int J Epidemiol. 1990;19:66-71.
34. Charlton A. Children and passive smoking: a review. J Fam Pract. 1994;38:267-277.
35. Lassen K, Oei TP. Effects of maternal cigarette smoking during pregnancy on long-term physical and cognitive parameters of child development. Addict Behav. 1998;23:635-653.
36. Eskenazi B, Bergmann JJ. Passive and active maternal smoking during pregnancy, as measured by serum cotinine, and postnatal smoke exposure, I: effects on physical growth at age five years. Am J Epidemiol. 1995;142(9 suppl):S10-S18.
37. Abrams EJ, Matheson PB, Thomas PA, et al. Neonatal predictors of infection status and early death among 332 infants at risk of HIV-1 infection monitored prospectively from birth. Pediatrics. 1995;96:451-458.
38. European Collaborative Study. Hospitalization of children born to human immunodeficiency virus-infected women in Europe. Pediatr Infect Dis J. 1997;16:1151-1156.
39. European Collaborative Study. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics. 2001;108:116-122.
40. Bamji M, Thea DM, Weedon J, et al. Prospective study of human immunodeficiency virus 1-related disease among 512 infants born to infected women in New York City. Pediatr Infect Dis J. 1996;15:891-898.
41. Rosenzweig D. Tuberculosis and nontuberculous mycobacterial diseases. In: Noble J, ed. Textbook of Primary Care Medicine. 3rd ed. St. Louis, MO: Mosby, Inc.; 2001:669-676.
42. Dei-Cas E. Pneumocystis infections: the iceberg? Med Mycol. 2000; 38(suppl 1):23-32.
43. Stagno S, Pifer LL, Hughes WT, Brasfield DM, Tiller RE. Pneumocystis carinii pneumonitis in young immunocompetent infants. Pediatrics. 1980;66:56-62.
44. Nevez G, Totet A, Pautard JC, Raccurt C. Pneumocystis carinii detection using nested-PCR in nasopharyngeal aspirates of immunocompetent infants with bronchiolitis. J Eukaryot Microbiol. 2001;(suppl):122S-123S.
45. American Academy of Pediatrics. Pneumocystis carinii infections. In: Pickering LK, ed. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000:460-465.
46. Centers for Disease Control and Prevention. CDC guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR. 1999;48(RR-13):29-31.
47. Greene O, Varghese A, Tuamokumo VF, Ashe WK, Ting P. Perinatal outcome after cocaine +/- polydrug exposure. Ann NY Acad Sci. 1998;846:396-398.
48. Bellini C, Massocco D, Serra G. Perinatal cocaine exposure and the expanding spectrum of brain malformations. Arch Intern Med. 2000; 160:2393.
49. Bateman DA, Chiriboga CA. Dose-response effect of cocaine on newborn head circumference. Pediatrics. 2000;106:e33.
50. Turpin DB, Matthews YL, Cooper NJ, et al. HIV infection in pregnant women: 12-year trends in the Women and Infants Transmission Study (WITS). Paper presented at: 2003 HIV Prevention Conference; 2003; Atlanta, GA. Abstract T-B12-03.
51. Paul M, Frederick M, Chantry C, et al. Morbidity among 940 uninfected children born to HIV-1 infected women as measured by CDC clinical disease classification. Presented at: Annual Meeting of the Pediatric Academic Societies, April 28-May 1, 2001, Baltimore, Maryland. Abstract 75.